1ly2: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Human complement receptor type 2 (CD21) is the cellular receptor for, Epstein-Barr virus (EBV), a human tumor virus. The N-terminal two short, consensus repeats (SCR1-SCR2) of the receptor interact with the EBV, glycoprotein gp350/220 and also with the natural CD21 ligand C3d. Here we, present the crystal structure of the CD21 SCR1-SCR2 fragment in the, absence of ligand and demonstrate that it is able to bind EBV. Based on a, functional analysis of wild-type and mutant CD21 and molecular modeling, we identify a likely region for EBV attachment and demonstrate that this, region is not involved in the interaction with C3d. A comparison with the, previously determined structure of CD21 SCR1-SCR2 in complex with C3d, shows that, in both cases, CD21 assumes compact V-shaped conformations., However, our analysis reveals a surprising degree of flexibility at the, SCR1-SCR2 interface, suggesting interactions between the two domains are, not specific. We present evidence that the V-shaped conformation is, induced by deglycosylation of the protein, and that physiologic, glycosylation of CD21 would result in a more extended conformation, perhaps with additional epitopes for C3d binding.
Human complement receptor type 2 (CD21) is the cellular receptor for Epstein-Barr virus (EBV), a human tumor virus. The N-terminal two short consensus repeats (SCR1-SCR2) of the receptor interact with the EBV glycoprotein gp350/220 and also with the natural CD21 ligand C3d. Here we present the crystal structure of the CD21 SCR1-SCR2 fragment in the absence of ligand and demonstrate that it is able to bind EBV. Based on a functional analysis of wild-type and mutant CD21 and molecular modeling, we identify a likely region for EBV attachment and demonstrate that this region is not involved in the interaction with C3d. A comparison with the previously determined structure of CD21 SCR1-SCR2 in complex with C3d shows that, in both cases, CD21 assumes compact V-shaped conformations. However, our analysis reveals a surprising degree of flexibility at the SCR1-SCR2 interface, suggesting interactions between the two domains are not specific. We present evidence that the V-shaped conformation is induced by deglycosylation of the protein, and that physiologic glycosylation of CD21 would result in a more extended conformation, perhaps with additional epitopes for C3d binding.


==Disease==
==Disease==
Line 16: Line 16:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Fingeroth, J.D.]]
[[Category: Fingeroth, J D.]]
[[Category: Prota, A.E.]]
[[Category: Prota, A E.]]
[[Category: Sage, D.R.]]
[[Category: Sage, D R.]]
[[Category: Stehle, T.]]
[[Category: Stehle, T.]]
[[Category: NAG]]
[[Category: NAG]]
[[Category: complement receptor; epstein barr virus; regulator of complement activation; short consensus repeat; viral receptor; complement control protein]]
[[Category: complement receptor; epstein barr virus; regulator of complement activation; short consensus repeat; viral receptor; complement control protein]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 16:21:09 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 13:49:30 2008''